US 11,674,155 B2
Sequential gene editing in primary immune cells
Jean-Pierre Cabaniols, Saint Lau la Foret (FR); Jean-Charles Epinat, Les Lilas (FR); and Philippe Duchateau, Draveil (FR)
Assigned to CELLECTIS, Paris (FR)
Filed by CELLECTIS, Paris (FR)
Filed on Aug. 5, 2022, as Appl. No. 17/817,877.
Application 17/817,877 is a continuation of application No. 16/314,697, granted, now 11,466,291, previously published as PCT/EP2017/066355, filed on Jun. 30, 2017.
Claims priority of application No. PA 201670503 (DK), filed on Jul. 6, 2016.
Prior Publication US 2023/0087122 A1, Mar. 23, 2023
Int. Cl. C12N 15/86 (2006.01); C12N 5/0783 (2010.01); C12N 9/22 (2006.01); C12N 13/00 (2006.01); C12N 15/113 (2010.01); C12N 15/90 (2006.01)
CPC C12N 15/86 (2013.01) [C12N 5/0636 (2013.01); C12N 9/22 (2013.01); C12N 13/00 (2013.01); C12N 15/113 (2013.01); C12N 15/902 (2013.01); C12N 2310/20 (2017.05); C12N 2510/00 (2013.01); C12N 2800/80 (2013.01)] 17 Claims
 
1. A pair of PD-1-targeting TALE nuclease (TALEN) monomers comprising:
1) A TALEN monomer comprising the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 9; and
2) A TALEN monomer comprising the amino acid sequence of SEQ ID NO: 6.